CELL & GENE THERAPY ADVANCEMENTS ONLINE SUMMIT

3 - 4 November 2021

Gain access to the latest research on: CRISPR | Immuno-oncology | AAV vectors | Cell and gene therapy
CAR T-cell therapies | Gene therapy | Regenerative medicine

Brought to you by

0 +
Pharmaceutical Companies
0 +
Attendees
0 +
Leading Scientific Speakers
0 +
Countries

Why attend?

As advancements in cell and gene therapies continue to accelerate and reach the clinic, the spotlight is now focused on improving safety, efficacy and scale-up at the pre-clinical stage.

Drug Target Review’s new virtual summit will explore the latest developments in cell and gene therapies. In this two-day online conference, gain access to the latest research from leading scientists and experts.

Speakers from global pharmaceutical companies, biotech organizations, CROs and academic institutes will present the latest innovations in the application of cell and gene therapies across a range of indications and how researchers can work towards delivering innovative treatments to patients.  

Please note that the free pass is limited to active researchers from pharmaceutical companies, biotech organisations, research centres, academic institutes and CROs.

Confirmed Speakers

Leading scientists and experts from global pharmaceutical companies, biotech organizations, CROs and academic institutes at the forefront of cell and gene therapy advancements will present their latest research and case studies throughout the two days.   

Confirm Your Attendance

FREE Pass

Watch and take part in all presentations / sessions LIVE and on-demand, ask questions, take part in polls, access and contact the attendees, send messages and schedule meetings.

FREE PASS

Please note that this free pass is limited to active researchers from pharmaceutical companies, biotech organisations, research centres, academic institutes and CROs
Applications will only be accepted with a company email address

Attendees

Watch and take part in all presentations / sessions LIVE and on-demand, ask questions, take part in polls, access and contact the attendees, send messages and schedule meetings.

EARLY BIRD PRICE

£999*

£400 Saving!

*Early bird expires 08 September 2021 (Ex VAT where applicable)

Agenda

During this online conference, you will hear from leading scientists and experts from pharmaceutical companies, biotech organizations, CROs and academic institutes at the forefront of innovation in immuno-oncology, genome editing, stem cell therapies and personalized medicine

The virtual summit will give over 1,000 global attendees specializing in biologics discovery and development access to the latest research in cell and gene therapies. 

Day 1

CRISPR – where we are and what’s next

Adoptive cell therapy approaches for immuno-oncology

Combatting the immune response to AAV vectors

Cell and gene therapy – the road to treating Parkinson’s disease

Day 2

Utilising CAR T-cell therapies against solid tumours

Case study: retinal diseases

The potential of gene therapy to treat Alzheimer’s 

Regenerative medicine – stem cell therapies 

Attendees

Over 1,000 scientists, researchers and  experts from across the globe from pharmaceutical companies, biotech organizations, CROs and academic institutes focused on driving innovation across cell & gene therapy advancements.

Join scientists and experts driving innovation in Cell & Gene Therapy Advancements

If you are part of a pharmaceutical company, biotech organizations, CRO or an academic institutes you can attend this online summit for FREE. Apply for your free pass today.

All other attendees can take advantage of our early bird discounts and make sure you don’t miss out accessing the latest research in immuno-oncology, genome editing, stem cell therapies and personalized medicine.

Sponsorship Opportunities

Get in touch to discuss your branding and speaking involvement for our 2021 events

Access speaking opportunities to position your brand as a thought leader, generate qualified leads, create brand awareness and receive detailed analytics. We commit to providing you full onboarding and support, as well as helping you deliver ROI.

Get Involved

  • Showcase your thought leadership message
  • Conduct video meetings with new and existing clients
  • Network with industry peers
  • Engage with the community and stay front of mind
Fraser Owen

View Sponsorship Brochure

Fill out the form below to find out about our speaking, exhibition and branding opportunities.






    By submitting this form you confirm that you accept our terms and conditions and privacy policy

    2021 Sponsors

    Exclusive: Cell & Gene Therapy Advancements Whitepaper

    Download this whitepaper to discover the latest research and developments in cell and gene therapies via exclusive articles and interviews. 

    Considering the growing number benefits that cell and gene therapies have provided when treating a wide range of conditions, researchers around the world have turned their attention to this next-generation class of biologics. From lower dosages to longer-lasting effects, the advantages of these therapies mean that scientists are working to accelerate them towards the clinic. In the original pieces listed below, experts in this whitepaper discuss the most recent progress in cell and gene therapies, from immuno-oncology to gene therapy for ocular conditions to stem cells. 

    Included in this whitepaper:

    • Lentiviral vectors: the key to cancer treatments that CAR T-cell therapy cannot reach?
      Professor Christian Brechot, TheraVectys
    • How engineered RNA binding proteins delivered in vivo by gene therapy could treat myotonic dystrophy
      Dr Jim Burns, Locanabio
    • Off-the-shelf T-cell therapy from gene edited stem cells
      Dr Jo Brewer, Adaptimmune
    • Glycolytic-pathway inhibition and CTLA-4 blockade to improve immuno-oncology
      Dr Taha Merghoub, Memorial Sloan Kettering and Ludwig Cancer Research
    • Challenges and opportunities in gene therapy development 
      Dr Carsten Brunn, Selecta Biosciences
    • How RNA therapeutics can be used to treat retinitis pigmentosa
      Sahm Nasseri, PYC Therapeutics
    Cell & Gene Therapy Whitepaper